Can a person develop a second episode of infectious mononucleosis (EBV) or experience recurrence?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 25, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Can You Get Mono Again?

True recurrent infectious mononucleosis is extremely rare in immunocompetent individuals, but EBV reactivation causing mono-like symptoms can occur, particularly in immunocompromised patients or those with chronic active EBV infection (CAEBV).

Understanding EBV After Initial Infection

After primary EBV infection, the virus establishes lifelong latency in B lymphocytes. In healthy individuals, the immune system typically keeps the virus suppressed, making a second full episode of classic infectious mononucleosis highly unusual. However, the clinical picture is more nuanced than a simple yes or no answer.

When "Mono Again" Can Happen

1. True Recurrence (Very Rare)

A documented case report describes a 28-year-old immunocompetent man who experienced recurrence of infectious mononucleosis 3 years after initial remission, presenting with fever, pharyngalgia, fatigue, tonsil enlargement, and elevated liver enzymes with confirmed EBV reactivation 1. This demonstrates that while uncommon, true recurrence is possible even in otherwise healthy adults.

2. Chronic Active EBV Infection (CAEBV)

Some patients develop persistent or recurrent mono-like symptoms characterized by:

  • Intermittent or persistent fever
  • Lymphadenopathy and hepatosplenomegaly
  • Elevated anti-VCA IgG (≥1:640) and anti-EA IgG (≥1:160)
  • EBV DNA loads >10^2.5 copies/mg DNA in peripheral blood
  • Symptoms lasting months to years 2

Critical distinction: CAEBV is a distinct clinical entity from typical infectious mononucleosis and carries significant morbidity risk, including potential progression to hemophagocytic lymphohistiocytosis or T-cell/NK-cell lymphomas 2.

3. Immunocompromised Patients

EBV reactivation causing mono-like illness occurs more readily in patients with:

  • Primary immunodeficiency disorders
  • HIV/AIDS
  • Immunosuppressive medications (methotrexate, tocilizumab, transplant medications)
  • Concurrent infections like COVID-19 3

A 60-year-old man on immunosuppression for rheumatoid arthritis developed infectious mononucleosis from EBV reactivation during COVID-19 infection, demonstrating that age-atypical presentations can occur when immunity is compromised 3.

Clinical Patterns to Recognize

Protracted Symptoms After Initial Infection

Historical data shows that patients who develop antibodies to the R component of EBV early antigen may experience recurrent symptoms resembling acute mono for 4-28 months after initial infection, with anti-R antibodies persisting up to 39 months 4. These patients often have persistently elevated anti-VCA titers, suggesting ongoing viral activity.

Chronic Mononucleosis Syndrome

Approximately 57% of patients with chronic symptoms and serologic evidence of EBV reactivation achieved temporary remission after an average of 33 months, though sustained remission was rare 5. This syndrome typically presents with:

  • Disabling fatigue
  • Average age of onset 29.6 years
  • Partial hypogammaglobulinemia in 71%
  • Often concurrent CMV seropositivity (86%)

Diagnostic Approach When Suspecting Recurrence

If a patient presents with mono-like symptoms and reports prior infectious mononucleosis:

  1. Obtain EBV-specific antibody panel (not just heterophile test):

    • Anti-VCA IgM (suggests recent/acute infection)
    • Anti-VCA IgG (elevated >1:640 suggests reactivation)
    • Anti-EA IgG (elevated >1:160 suggests active replication)
    • Anti-EBNA (typically positive in past infection)
  2. Consider quantitative EBV PCR if antibodies suggest reactivation (>10^2.5 copies/mg DNA in peripheral blood is significant) 2

  3. Evaluate for immunocompromise:

    • HIV testing
    • Review medications
    • Check immunoglobulin levels
    • Consider T-cell subset analysis if CAEBV suspected
  4. Rule out alternative diagnoses:

    • CMV (common cause of heterophile-negative "mono")
    • Toxoplasmosis
    • Acute HIV
    • Lymphoma (especially if atypical features present)

Common Pitfalls to Avoid

  • Don't rely on heterophile antibody testing alone for suspected recurrence—it may be negative in reactivation and is not specific for EBV
  • Don't dismiss persistent symptoms as "post-viral fatigue" without proper EBV serologic evaluation and exclusion of CAEBV, which requires specific diagnostic criteria 2
  • Don't assume all "mono-like" illnesses are EBV—CMV causes a significant proportion of adult infectious mononucleosis cases 6
  • Be vigilant for complications in patients with confirmed CAEBV, as this entity carries risk of hemophagocytic lymphohistiocytosis and lymphoproliferative disorders with poor prognosis 2

Bottom Line for Clinical Practice

For the typical patient asking "can I get mono again," the answer is that classic infectious mononucleosis from a second EBV infection is extremely unlikely in healthy individuals. However, EBV reactivation causing similar symptoms can occur, particularly with immunosuppression. Any patient with recurrent mono-like symptoms warrants EBV-specific serologic testing and evaluation for underlying immunodeficiency or CAEBV, as these conditions have significant implications for morbidity and require long-term monitoring 1.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.